Navegando por Palavras-chave "calcinose"

Agora exibindo 1 - 3 de 3
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Calcinose na infância, um desafio terapêutico
    (Sociedade Brasileira de Reumatologia, 2007-02-01) Castro, Tânia Caroline Monteiro de [UNIFESP]; Yamashita, Edson [UNIFESP]; Terreri, Maria Teresa Ramos Ascensão [UNIFESP]; Len, Claudio Arnaldo [UNIFESP]; Hilário, Maria Odete Esteves [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Calcinosis is a common and debilitating complication of dermatomyositis. It is a hallmark of the disease, occurring mainly in pediatric patients. Little is known about its pathophysiology, and there is no universally recognized treatment. This is a report of two children with juvenile dermatomyositis and severe calcinosis who showed improvement with the use of alendronate and diltiazen in one patient, and intravenous immunoglobulin in the other.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Frequência elevada de calcinose em dermatomiosite juvenil: estudo de fatores de risco
    (Sociedade Brasileira de Reumatologia, 2012-08-01) Clemente, Gleice [UNIFESP]; Piotto, Daniela Gerent Petry [UNIFESP]; Barbosa, Cassia Maria Passarelli Lupoli [UNIFESP]; Peracchi, Octávio Augusto Bedin [UNIFESP]; Len, Claudio Arnaldo [UNIFESP]; Hilário, Maria Odete Esteves [UNIFESP]; Terreri, Maria Teresa Ramos Ascensão [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    OBJECTIVE: To assess the frequency of calcinosis in patients with juvenile dermatomyositis, and the possible risk factors for that manifestation. METHODS: Medical record review of 34 patients, with an emphasis on the following characteristics: demographic, clinical and laboratory data; type of treatment; adherence to treatment; disease course (monocyclic, chronic and polycyclic); and disease severity. Patients were divided into two groups as follows: those who developed calcinosis (up to the sixth month of follow-up and after six months of follow-up) and those who did not develop calcinosis. Twentyseven patients underwent two nailfold capillaroscopies (NFC), which were considered altered when the scleroderma pattern was found. RESULTS: The mean age of symptom onset of the 34 patients was 6.5 years, the time until diagnosis was 1.2 years, and 70% were females. Half of the patients had a monocyclic disease course, and only 14.7% had severe vasculitis. Almost 90% of the patients undergoing NFC showed a change on the first assessment, 74% showed a change on the second assessment, and the mean interval between both assessments was 1.6 year. Calcinosis was evidenced in 16 (47.1%) patients. No association was observed between the variables analyzed and the development of calcinosis. CONCLUSION: No risk factors for calcinosis were identified in this study, although that complication was found in half of the patients with juvenile dermatomyositis studied.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Linhas escleróticas metafisárias em crianças e adolescentes em uso de alendronato
    (Sociedade Brasileira de Reumatologia, 2010-06-01) Silva, Érika Cristina Carneiro da [UNIFESP]; Terreri, Maria Teresa Ramos Ascensão [UNIFESP]; Castro, Tania Caroline Monteiro de [UNIFESP]; Barbosa, Cassia Maria Passarelli Lupoli [UNIFESP]; Fernandes, Artur da Rocha Correa [UNIFESP]; Hilário, Maria Odete Esteves [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    INTRODUCTION: Bisphosphonates inhibit bone resorption by interfering with the action of osteoclasts. Among the adverse effects, sclerotic lines observed in the metaphysis of long bones have been described as the main imaging finding in pediatric patients. OBJECTIVE: To evaluate the frequency of radiographic changes caused by alendronate in children and adolescents with low bone density or calcinosis. PATIENTS AND METHODS: We conducted a cross-sectional study with 21 patients who were treated with once-weekly alendronate for at least 10 months. Patients underwent x-rays of long bones before the start of alendronate and approximately one year after its use. RESULTS: Eleven patients (52.3%) had sclerotic lines in the metaphysis of long bones. The most frequent site was the tibia (8/11 patients), followed by the femur (7/11), humerus (6/11), radius (4/11), ulna (3/11), and fibula (2/11). Regression of radiographic changes during the study period (up to 1.1 years after discontinuation of alendronate) was not observed. CONCLUSION: If used carefully, alendronate is safe and radiographic changes have not been shown to be clinically relevant.